YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.
The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.
